China’s clinical trial infrastructure on West Coast delivers up to 60% cost savings

China is becoming a hub for innovative drug development, with a clinical trial environment that offers significant cost savings and accelerated timelines for drug discovery. According to discussions at the Outsourcing in Clinical Trials West Coast conference, China has emerged as a cost-effective and time-efficient option for clinical trials on a global scale.

GlobalData, the parent company of Clinical Trials Arena, reports that clinical trials in China account for around 30% of all clinical trials worldwide. This growth in the number of trials conducted in China has increased sixfold since 2016, showcasing the country’s expanding role in the global clinical trial landscape.

Clinical trials in China offer a substantial cost advantage over trials conducted in the US, with savings of up to 50-60%. Revati Tatake, Global head of Pharma and Competitive Intelligence at GlobalData, highlights that China demonstrates considerable speed advantages in Phase I and Phase II clinical trials compared to other regions, particularly for non-oncology indications, with trials being 60-70% faster in certain cases.

The combination of lower costs and faster timelines in China’s clinical trial infrastructure has become a key driver for the pharmaceutical industry in the country. This dual benefit of cost-effectiveness and efficiency makes China an attractive option for early-phase studies and drug development.

Recent regulatory changes in China have further contributed to the growth of clinical trials in the country. The introduction of data exclusivity protection in 2025 addressed historical concerns about intellectual property rights, providing a more favorable environment for drug development. The National Medicinal Products Administration (NMPA) in China has implemented measures to streamline the approval process for clinical trial applications, reducing the average review timeline to 50 working days. Additionally, the NMPA introduced a pilot program in 2024 to expedite reviews for innovative therapies, leading to the establishment of a 30-day expedited review pathway for high-priority innovative drugs.

The supportive regulatory landscape, coupled with cost-effective and time-efficient clinical trials, has positioned China as a key player in drug discovery and development. The growing trend of conducting clinical trials in China reflects the country’s emergence as a leader in innovative pharmaceutical research. With a robust clinical trial infrastructure and regulatory framework, China offers a compelling and competitive environment for the pharmaceutical industry to advance drug discovery and deliver innovative therapies to patients worldwide.